history of glp-1 drugs Continued growth for receptor agonists and SGLT-2 inhibitors in 2017 Reflections on the discovery GLP-1
Description
more below) Peripheral nerves: Gutbrain axis signaling These effects come with trade-offs

participants aged 18 years who were overweight or have obesity, defined as having a BMI 25 kg/m 2 (or 23 kg/m 2 for Japanese and 24 kg/m2 for Chinese) [4]

Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes
[DOI] [PMC free article] [PubMed] [Google Scholar] 85.Oh A.R., Lee D.Y., Lee S., et al
2024;54(12):e14292

doi: 10.1681/ASN.2013101067
